- Home
- DMAC vs ACB Comparison
DMAC vs ACB Comparison
Compare DMAC & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- ACB
- Stock Information
- Founded
- DMAC 2000
- ACB 2013
- Country
- DMAC United States
- ACB Canada
- Employees
- DMAC N/A
- ACB N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- ACB Pharmaceuticals and Biotechnology
- Sector
- DMAC Health Care
- ACB Health Care
- Exchange
- DMAC Nasdaq
- ACB Nasdaq
- Market Cap
- DMAC 310.1M
- ACB 256.5M
- IPO Year
- DMAC N/A
- ACB N/A
- Fundamental
- Price
- DMAC $6.96
- ACB $6.10
- Analyst Decision
- DMAC Strong Buy
- ACB
- Analyst Count
- DMAC 3
- ACB 0
- Target Price
- DMAC $12.33
- ACB N/A
- AVG Volume (30 Days)
- DMAC 343.5K
- ACB 1.9M
- Earning Date
- DMAC 11-12-2025
- ACB 11-05-2025
- Dividend Yield
- DMAC N/A
- ACB N/A
- EPS Growth
- DMAC N/A
- ACB N/A
- EPS
- DMAC N/A
- ACB N/A
- Revenue
- DMAC N/A
- ACB $262,403,032.00
- Revenue This Year
- DMAC N/A
- ACB $9.42
- Revenue Next Year
- DMAC N/A
- ACB $5.72
- P/E Ratio
- DMAC N/A
- ACB N/A
- Revenue Growth
- DMAC N/A
- ACB 28.58
- 52 Week Low
- DMAC $3.19
- ACB $3.42
- 52 Week High
- DMAC $7.49
- ACB $6.91
- Technical
- Relative Strength Index (RSI)
- DMAC 58.60
- ACB 62.58
- Support Level
- DMAC $6.75
- ACB $5.55
- Resistance Level
- DMAC $7.13
- ACB $6.51
- Average True Range (ATR)
- DMAC 0.28
- ACB 0.32
- MACD
- DMAC -0.06
- ACB 0.08
- Stochastic Oscillator
- DMAC 50.00
- ACB 72.94
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.